AstraZeneca partners with ‘India - Sweden Healthcare Innovation Centre’ at AIIMS to accelerate uptake of innovative health technology

Chairman Leif Johansson’s second visit this year emphasizes AstraZeneca’s commitment to spur healthcare technology and innovation in India

New Delhi, 03 December 2019: AstraZeneca India, leading science-led biopharmaceutical company with roots in Sweden and the UK, announced its role as Knowledge Partner to the India-Sweden Healthcare Innovation Centre, a collaboration between Swedish Trade Commissioner’s office, the All India Institute of Medical Sciences, New Delhi (AIIMS, New Delhi) and the All India Institute of Medical Sciences, Jodhpur (AIIMS, Jodhpur). The new Centre was unveiled at the India-Sweden Business Summit Inauguration held today in the presence of His Majesty King Carl XVI Gustaf of Sweden, the Honourable Minister Smt. Nirmala Sitharaman, Finance, Government of India, and Minister Mr. Ibrahim Baylan, Ministry of Enterprise and Innovation, Government of Sweden. AstraZeneca was represented by its Chairman of the Board, Mr. Leif Johansson, who shared Swedish industry perspectives in remarks at the Summit.

The India-Sweden Healthcare Innovation Centre aims to accelerate the uptake of innovative healthcare solutions  in clinics and hospitals across India, to make healthcare more patient-centric, affordable and accessible for patients. This supports the Government of India’s objectives to increase health and prosperity through Ayushman Bharat and ‘Make in India’. The Centre will provide a platform for Indian and foreign innovators to work side by side with leading doctors to ensure their solutions are suited to real-world medical settings, to bridge the gap between scientific invention and clinical implementation. The Centre will have a live Centre of Excellence to prove the effectiveness of integrated disease management and will be a hub for skill development.

Anders Wickberg, Trade Commissioner of Sweden to India, said, “This collaboration is built on the quadruple-helix model with the active participation of Government, academia, private enterprises and civil society. The broad vision of the collaboration is to strengthen the healthcare delivery system by an outcome and result based approach”.

Leif Johansson, Chairman of the Board, AstraZeneca Plc commenting on the innovation centre said, “AstraZeneca is honoured to partner with AIIMS and the Swedish Trade Commissioner’s Office to further innovation in healthcare. The centre will mainstream digital, scalable and affordable healthcare solutions for early diagnosis and digital intervention in the management of Non-Communicable Diseases (NCDs) such as diabetes and cancer, a shared challenge for India and Sweden”

This announcement is in line with AstraZeneca’s commitment to collaborate with partners to provide end to end healthcare solutions supported by technology and furthers the company’s USD 90 million investment announcement made in the presence of Honourable Prime Minister of India in Stockholm’ 2018.

During Leif Johansson’s visit to India early this year, AstraZeneca launched a strategic partnership with the NASSCOM Centre of Excellence for IoT under its iDREAM programme to set up an accelerator programme to identify frugal and scalable digital interventions for early diagnosis and digitally enabled management of NCDs. Three promising start-ups have been identified as part of this programme through a hackathon – Predible Health, Ten3T and Pathshodh.  AstraZeneca also facilitated a partnership with NASSCOM and China’s Wuxi International Life Science Innovation Campus (I·Campus), an innovation incubation platform co-created with AstraZeneca to accelerate cooperation in the life sciences & healthcare sector. Tricog, an Indian healthcare technology start-up that uses artificial intelligence to diagnose and manage heart attacks also partnered with I·Campus to expand their solution to patients in China earlier this year.  

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZeneca.

About AstraZeneca India

AstraZeneca is present in India through 2 legal entities:

  • AstraZeneca Pharma India Limited (AZPIL), a listed company, established in 1979 and headquartered in Bengaluru, Karnataka has a workforce of over 1400 employees and is the operating company covering manufacturing, sales and marketing activities. It is listed on the Indian Stock Exchanges. It has an innovative portfolio to address the unmet needs in non-communicable diseases such as diabetes, heart disease, cancer, asthma &COPD.
  • AstraZeneca India Private Limited (AZIPL), is a private entity, established in 1986, covering AZ’s Global Technology Centre (GTC) in Chennai with a workforce of more than 2000 employees. It also includes AstraZeneca’s R&D Unit and the digital unit - Global Business Services.



Varsha Das

Corporate Affairs, AstraZeneca Pharma India Limited; +91.9008777884